Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

The company will begin filing to global regulators in the first half of 2026. Read more at straitstimes.com. Read more at ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

You've probably heard about the gene-editing technology CRISPR. The massive biotech breakthrough, which has emerged in the last decade, has mainly been touted for the ways it will let scientists edit ...

Higher yields, greater resilience to climatic changes or diseases—the demands on crop plants are constantly growing. To ...

Thinking about whether CRISPR Therapeutics stock is truly a bargain or just the next biotech craze? Let’s break down its value case together. After a sharp rally earlier this year, the stock is still ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the most oversold biotech stocks to invest in. Following the company’s third ...

The new GE technology — for which the Indian Council of Agricultural Research (ICAR) has recently been granted a patent — deploys the so-called TnpB or Transposon-associated proteins.